AXL signaling in cancer: from molecular insights to targeted therapies [0.03%]
癌症中的AXL信号通路：从分子机理到靶向治疗
Monika Yadav,Akansha Sharma,Ketki Patne et al.
Monika Yadav et al.
AXL, a member of the TAM receptor family, has emerged as a potential target for advanced-stage human malignancies. It is frequently overexpressed in different cancers and plays a significant role in various tumor-promoting pathways, includi...
Src inhibition potentiates MCL-1 antagonist activity in acute myeloid leukemia [0.03%]
Src抑制可增强MCL-1拮抗剂在急性髓系白血病中的活性
Xiaoyan Hu,Lin Li,Jewel Nkwocha et al.
Xiaoyan Hu et al.
The importance of MCL-1 in leukemogenesis has prompted development of MCL-1 antagonists e.g., S63845, MIK665. However, their effectiveness in acute myeloid leukemia (AML) is limited by compensatory MCL-1 accumulation via the ubiquitin prote...
Molecular mechanisms in liver repair and regeneration: from physiology to therapeutics [0.03%]
肝修复与再生的分子机制：从生理学到治疗学
Xiao Ma,Tengda Huang,Xiangzheng Chen et al.
Xiao Ma et al.
Liver repair and regeneration are crucial physiological responses to hepatic injury and are orchestrated through intricate cellular and molecular networks. This review systematically delineates advancements in the field, emphasizing the ess...
Mitochondrial heterogeneity: subpopulations with distinct metabolic activities [0.03%]
线粒体异质性：具有不同代谢活性的亚群
Fabian den Brave,Swadha Mishra,Thomas Becker
Fabian den Brave
Jiaojiao Zheng,Siying Wang,Lei Xia et al.
Jiaojiao Zheng et al.
Liver cancer represents a major global health concern, with projections indicating that the number of new cases could surpass 1 million annually by 2025. Hepatocellular carcinoma (HCC) constitutes around 90% of liver cancer cases and is pri...
Neoadjuvant apatinib addition to sintilimab and carboplatin-taxane based chemotherapy in patients with early triple-negative breast cancer: the phase 2 NeoSAC trial [0.03%]
新辅助阿帕替尼联合信迪利单抗和卡铂-紫杉类化疗治疗早期三阴性乳腺癌患者：NeoSAC II期临床试验
Guoshuang Shen,Zhilin Liu,Miaozhou Wang et al.
Guoshuang Shen et al.
We aimed to evaluate the efficacy and safety of adding apatinib, to sintilimab and chemotherapy in the neoadjuvant treatment of early triple-negative breast cancer (TNBC). In the phase 2 NeoSAC trial, patients with early TNBC received six c...
Perioperative tislelizumab plus chemotherapy for locally advanced gastroesophageal junction adenocarcinoma (NEOSUMMIT-03): a prospective, nonrandomized, open-label, phase 2 trial [0.03%]
特瑞普利单抗联合化疗治疗局部晚期胃食管结合部腺癌的围手术期疗效（NEOSUMMIT-03）：一项前瞻性、非随机、开放标签II期试验
Run-Cong Nie,Shu-Qiang Yuan,Ya Ding et al.
Run-Cong Nie et al.
This prospective, nonrandomized, open-label phase 2 trial (Chinese Clinical Trial Registry, ChiCTR2200061906) aimed to evaluate the effectiveness of adding the PD-1 antibody tislelizumab to perioperative chemotherapy in patients with locall...
Protecting cell cycle integrity: enhanced start-codon stringency in mitosis [0.03%]
保护细胞周期的完整性：有丝分裂中起始密码子严谨性增强
Omid Omrani,Kanstantsin Siniuk,Martin Fischer
Omid Omrani
Single-cell transcriptomics reveals novel chondrocyte and osteoblast subtypes and their role in knee osteoarthritis pathogenesis [0.03%]
单细胞转录组揭示了软骨细胞和骨细胞的亚型及其在膝关节炎发病机制中的作用
Yuan Liu,Wacili Da,Ming-Jie Xu et al.
Yuan Liu et al.
Research on treating knee osteoarthritis (KOA) is becoming more challenging due to a growing number of younger patients being affected. The pathogenesis of KOA is complex for being a multifactorial disease affecting the entire joint, with r...
Can Gan,Yuan Yuan,Haiyuan Shen et al.
Can Gan et al.
As a highly complex organ with digestive, endocrine, and immune-regulatory functions, the liver is pivotal in maintaining physiological homeostasis through its roles in metabolism, detoxification, and immune response. Various factors includ...